A Novel Cross-Immune Antigen Vaccine Platform for Influenza Virus Type A

Kenji Sekikawa; Haniyeh Bidadi; Miki Maeda; Liat Fux; Yakir Nataf; Hirofumi Komatsubara; Yutaka Komiyama; Osamu Kobayashi

doi:10.1248/bpb.b24-00337

Communication to the Editor

A Novel Cross-Immune Antigen Vaccine Platform for Influenza Virus Type A

Kenji Sekikawa , Haniyeh Bidadi, Miki Maeda, Liat Fux, Yakir Nataf, Hirofumi Komatsubara, Yutaka Komiyama, Osamu Kobayashi

著者情報

キーワード: influenza virus type A, universal vaccine, conformational epitope, oligomer, antigen-specific T-helper 1 (Th1) response

ジャーナルオープンアクセス HTML
電子付録

2024 年 47 巻 12 号 p. 2028-2031

DOI https://doi.org/10.1248/bpb.b24-00337

詳細

抄録

We have developed a novel cross-immune antigen vaccine platform for influenza A virus. The vaccine antigen is a fusion protein of headless hemagglutinin (HA) and matrix protein 1 (M1), which possess B-cell and T-cell epitopes, respectively, that are conserved among subgroup A viruses. The single molecule of headless HA and M1 fusion protein forms an oligomer by self-assembly of M1. T-Helper 1 (Th1) and Th2 cells were activated in an antigen-specific manner in lymphocyte cultures of antigen-immunized mice. The antigen-immunized antiserum neutralized influenza virus A subtypes H1N1 and H3N2, and intranasal administration of the antigen reduced mortality to less than 30% in a protection assay.

Fullsize Image

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）